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bstract
The gut microbiota continues to fascinate scientists in many realms when it is considered that humans contain 90% bacteria. Correlations between
hanges in composition and activity of the gut microbiota and common disorders such as cancer, hypertension, hypercholesterolemia, inflammatory
owel diseases, obesity, oral health, etc.  have been proposed. What is the real role of probiotics, prebiotics and synbiotics in influencing a healthy
icrobiota? Both in  vitro  evidences and in  vivo  clinical data have supported some of these new health claims, while recent molecular advancement
as provided strong indications to support and justify the hypotheses. However, probiotics validity and health claims have continuously been rejected
n the basis of “biomarker deficiency”. To battle the increase in health care costs, a preventive approach to medicine with the development of
robiotics and prebiotics or symbiotic products is being advanced. This review discusses the potential beneficial effects of probiotics in preventing
nd treating certain diseases as well as current and future perspectives of probiotic research.
 2015 Beijing Academy of Food Sciences. Production and hosting by Elsevier B.V. All rights reserved.
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.  Introduction
Food fermentation and the consumption of fermented foods
ate far beyond human civilization. The transition from hunting
nd gathering to an agricultural lifestyle might have contributed
o the further development of these food fermentations that are
ow practiced on industrial scales. However, human interactions
ith probiotics are more intimate and have a much longer history
han the historic food fermentations. All parts of the human body
uch as the skin, oral cavity, gastrointestinal tract, and vaginal
avity are inhabited by trillions of microbes [1,2]. At birth, the
uman gut is sterile but colonized immediately after birth [3].
actors such as the type of delivery (vaginal birth versus  cesarean
ection) and the type of diet (breast feeding versus  formula feed-
ng) affect the colonization patterns [4]. The pioneer microbes
hat ‘infest’ the gut make permanent adaptations and determine∗ Corresponding author at: Department of Food Science and Biotechnology,
angwon National University, Chuncheon 200-701, South Korea.
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ent and also influence future disease susceptibility [132]. Age
nd life style are some causes of many disease conditions since
hey contribute to alterations in the microbial flora in the body
5]. Recent studies have demonstrated that bacterial community
omposition is considerably altered in diseases such as obesity
nd periodontal disease, with healthy subjects usually exhibit-
ng distinct, diverse and temporally stable bacterial populations
t these sites when compared with patients displaying disease
ymptoms [6]. As consumers become aware of the impact of
hat they eat on their health, they tend to search for functional
oods. Attention has been paid to prevention of diseases than
ure and hence, probiotic containing foods are abundant on the
arket.
.  Diseases  and  disorders  caused  by  alterations  in  the
uman gut  microbiotaIt is evident that prenatal maternal exposure influences post-
atal microbial colonization [3] and this plays pivotal roles
n gut-associated lymphoid tissue (GALT) development [7],
pecific aspects of immune system development [8,9] and the
lsevier B.V. All rights reserved.
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Table 1
Diseases and disorders caused by alterations in the gut microbiome.
Disease/disorder Potential role of the microbiome Recent findings
Atopy and asthma • Pre- and postnatal microbial exposures influence
immune development [3].
• Mode of delivery and nutrient uptake influence
GI community development and protection against
subsequent atopic disease development [13].
• Infants born by cesarean section are more often colonized with
Staphylococcus, Corynebacterium and Propionibacterium and less with
bifidobacteria and lactobacilli while vaginally delivered infants are colonized
with Lactobacillus, Prevotella or Sneathia [14].
• Streptococcus, Clostridium species, Bacillus subtilis, Bacteroides vulgatus
and Veillonella parvula are predominant in formula fed infants making them
prone to allergic and autoimmune diseases [15].
Candida infection • Depletion of gut microbiota permits Candida
albicans proliferation and infection [131].
• Depletion of the gut microbiome through antibiotic administration is
associated with increased C. albicans abundance and infection [131].
Celiac disease • The GI of celiac disease patients contain large
populations of Gram negative bacteria compared
to healthy individuals [130].
• Pediatric celiac disease patients have significantly higher numbers of
Bacteroides, Staphylococcus, Salmonella, Shighella and Klebsiella relative to
healthy subjects [130].
• The ratio of Lactobacillus–Biﬁdobacterium species to Bacteroides–E. coli
was lower for celiac disease patients [16].
Colorectal cancer • High abundances of Bacteroides spp. and
Clostridium spp. are present in the GI of CC
patents [17].
• Overall bacterial diversity increased for CC patients compared with healthy
controls [18].
• Microbial butyrate production causes apoptosis of CC cells [18].
Type I diabetes •  Interaction between the gut community and
innate immune system may be a predisposing
factor for diabetes [19].
• The microbiome plays a role in the development
of insulin resistance [20].
•  Metabolic profiling reveals a contribution of gut microbiota to fatty liver
phenotype in insulin-resistant mice [20].
• The intestinal microbiota interacts with environmental factors and susceptible
genetic factors, contributing to the development of diabetes [21].
Type II diabetes • Gut microbiome dysbiosis is critical for
pathogenesis [22].
• Low levels of Roseburia intestinalis and Faecalibacterium prausnitzii in the
microbiome of Type II diabetics [22].
• Type II diabetes and obesity are highly influenced by gut microbiome [23].
• Gut microbiota may contribute to insulin sensitivity and cause low-grade
systemic inflammation [20].
HIV • Gut microbiome dysbiosis may be critical for
pathogenesis [24].
• An important relationship exists between altered mucosal bacterial
communities and intestinal inflammation during chronic HIV-1 infection [25].
• HIV-1-infected subjects had increased abundances of Proteobacteria and
decreased abundances of Firmicutes compared with uninfected donors [24].
IBD • Composition of gut microbiota contributes to
inflammation [3].
• Treg-promoting organisms are depleted;
overgrowth of bacteria that induce
proinflammatory Th17 cell populations [26].
Crohn’s disease (IBDC)
• IBDC patients have high levels of Enterobacteriaceae, Pasteurellacaea,
Veillonellaceae, and Fusobacteriaceae, and decreased abundance in
Erysipelotrichales, Bacteroidales, and Clostridiales [27].
• IBDC patients have abnormal increase in antimicrobial dual oxidase
(DUOX2) expression with increasing numbers of proteobacteria [28]
• Fecal samples of CD patients have increased levels of Bacteroides fragilis (B.
fragilis) reletive to control samples [129].
• An overall decrease in microbial diversity is observed in CD patients [128].
• CD patients have significant alterations in oxidative stress pathways, as well
as decreased carbohydrate metabolism and amino acid biosynthesis in favor of
nutrient transport and uptake [128].
• CD patients have leucine, isoleucine, valine, lysine, alanine, tyrosine,
phenylalanine, glycine, glutamate, and aspartate malabsorption [29].
• Microbial diversity lower when compared with healthy individuals [29].
Ulcerative colitis (IBDU)
• Lower levels of Bifidobacteria and Clostridium leptum [30] reported relative
to healthy individuals.
• TRUC gut microbiomes with active colitis has a reduced potential for both
carbohydrate and energy metabolism and an enhanced potential for flagellar
assembly, tetrathionate respiration and benzoate degradation [31].
IBS • Disturbances of mucosa-associated bacteria may
be important in the pathogenesis of IBS symptoms
[32].
• Abnormal detection of hydrogen and methane in patients’ breath suggests
changes in bacterial fermentation [33].
• In children, a fecal microbiome with increased percentage of Haemophilus
parainﬂuenzae as well as bacterial taxa from the genus Alistipes characterizes
IBS [32].
Gastroenteritis • Pathogenic species capitalize on GI microbial
community disruption to elicit infection [34].
•  Helicobacter pylori capitalizes on host disruption of GI microbiome to induce
persistent inflammatory infiltration and can cause gastropathy and cancer [35].
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Table 1 (Continued)
Disease/disorder Potential role of the microbiome Recent findings
NEC • The interactions of a predisposing genetic
background, an immature intestinal barrier and a
conducive microbial environment in neonates play
critical roles in pathogenesis [36].
• The absence of Propionibacterium in the first
week of birth and the dominance of
Staphylococcus and Enterococcus indicate a risk
of NEC [37].
• There is lower bacteria diversity in all preterm infants, particularly NEC
infants [127].
• NEC patients had higher abundance of Gammaproteobacteria in the GI tract
[127].
• Lower bacterial diversity may favor certain dominant organisms, which
proliferate with the administration of antibiotics [36].
Obesity • Gastrointestinal microbiota impact adiposity via
interactions with epithelial and endocrine cells
[38].
• Differential energy harvest capacity by
microbiota may be a mechanism for the increased
adiposity in obese mice [39].
• Obese patients may depend on interspecies transfer of H2 between archaea
and bacteria to improve energy uptake [40].
• Obese individuals exhibit lower abundance of Bacteroidetes and a higher
abundance of Firmicutes compared with lean people [41].
• The ratio of Bacteroidetes and Firmicutes reverts back to a composition
similar to that of lean subjects following a diet and exercise regime [42].
Rheumatoid arthritis • Microbiome may be a causative agent underlying
certain rheumatic diseases like ankylosing
spondylitis and rheumatoid arthritis [43].
• Treg-promoting organisms depleted; overgrowth
of bacteria that induce Th17 cell populations,
leading to inflammation [26].
•  Patients with rheumatoid arthritis had high numbers of P. intermedia, P.
gingivalis and Prevotella nigrescens indicating the presence of the
chromosomal DNA of periodontal disease-associated bacteria in the sera and
synovial fluid of the patients [44].
• P. gingivalis could be involved in rheumatoid arthritis by generating
citrullinated proteins of itself as well as human antigen and the immune
response to them [45].
C C: irritable bowel disease-Crohn’s disease; IBDU: irritable bowel disease-ulcerative
c hns’ disease; TRUC: T-bet−/− Rag2−/− ulcerative colitis.
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Table 2
Properties and benefits of good probiotic strains.
Properties Benefits
• Resistance to pancreatic
enzymes, acid and bile
Survival of passage through the intestinal tract
• Adhesion to the
intestinal mucosa
Immune modulation; pathogen exclusion;
enhance healing of damaged mucosa; prolonged
transient colonization
• Human origin Species-dependent health effects and maintained
viability
• Production of
antimicrobial substrates
Antagonism against pathogenic microorganisms
• Documented health
effects
Proposed health effects are “true”; clinically
validated and documented health effects of
minimum effective dosage in products
• Health The assessment and proof of a ‘GRAS’ strain,
with a previous ‘history of safe use’ and safety
in food; non-pathogenic even in
immunocompromised hosts
• Good technology
properties
Strain stability; production at large scale;
oxygen tolerance
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sC: colon cancer; GI: gastrointestinal; IBD: inflammatory bowel disease; IBD
olitis; IBS: Irritable bowel syndrome; NEC: necrotizing enterocolitis; CD: Cro
ntegrity of the mucosal barrier [10]. Therefore the development
f the gut microbiota in the early stages of life may be linked
o future disease susceptibility. Many studies have associated
iseases such as Inflammatory bowel disease [3], obesity [6]
olon cancer [11] and some allergies [9] to alterations in the gut
icrobiome (Table 1). In many instances, there is an imbalance
n the population densities of gut microbiota (dysbiosis) and
his results in an overgrowth of pathogenic microbes. In obe-
ity, the altered microbial population is associated with a shift in
unction of the cells, resulting in increased energy harvest from
ngested food; unexpended excess energy is deposited as adipose
issue [12].
.  Probiotics  and  probiotic  selection  criteria
Probiotics are live microorganisms which, when adminis-
ered in adequate amounts, confer health effects on the host
nd prebiotics are non-digestible food ingredients that stim-
late the growth and or activity of probiotics [125]. Though
ome non-living cells may have probiotic properties [46,47]
iving cells tend to function better. The stomach is highly
cidic due to the presence of HCl. Therefore, one of the first
arriers probiotics must endure is the gastric acidity of the
tomach as well as the bile in the upper digestive tract before
hey get to the small intestines [35]. Many types of bacte-
ia have probiotic properties, however, the most documented
roups comprise of lactic acid bacteria (LAB) and bifidobac-
eria. While L.  casei  and Lactobacillus  acidophilus  survive
n the acidic conditions of artificial gastric juice at pH 3.0
◦t 37 C, Lactobacillus  delbruekii  ssp. bulgaricus  does not.
trains of Biﬁdobacterium  vary in their ability to survive tran-
it through the stomach. The initial screening and selection of
robiotics also include testing of the phenotype and genotype
s
g
a
Pdapted from Lee et al. [35].
tability, including plasmid stability; intestinal epithelial adhe-
ion properties; protein and carbohydrate utilization patterns;
roduction of antimicrobial substances; antibiotic resistance
atterns; ability to inhibit known pathogens, spoilage organ-
sms, or both; and immunogenicity [124]. Table 2 shows the
roperties and benefits of good probiotic strains. It is neces-
ary that probiotic strains survive, proliferate and colonize their
pecific locations. They must neither be pathogenic nor trig-
er allergic response in the host. However, they may serve as
djuvants to stimulate the immune system against pathogens.
ractically and for commercialization purposes, probiotics must
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e easily culturable on a large scale and must resist technologi-
al manipulations such as heating and low oxygen conditions in
ackages.
.  Functional  genomics  of  LAB
Recently, the number of sequenced LAB genomes has
ncreased exponentially and the genomic data from several LAB
pecies and strains are available to give a better understanding
f their gene content, their properties and their roles in human
ealth and food fermentation [48]. The most important LAB
sed as starters in dairy fermentations are Lactococcus  lactis,
treptococcus  thermophilus, L.  delbruekii  subsp. bulgaricus,
hile in some cases also some Leuconostoc  or other Lactobacil-
us spp. are used [49]. Because LAB do not contain a functional
espiratory system, they obtain energy by substrate level phos-
horylation. They use either the homofermentative pathway to
irtually produce only lactate or the heterofermentative path-
ay to produce large amounts of CO2, and ethanol in addition
o lactate. LAB compete with other bacteria based on their rapid
rowth and their lactic acid production in their habitats. Luesink
t al. [50] have reported that the main factor controlling sugar
egradation in LAB is the catabolite control protein CcpA which
cts as a transcriptional activator of the lactic acid synthesis (las)
peron with the order pfk-pyk-ldh. In many LAB, the ccpA  gene
s colocated with the prolidase-encoding pepQ gene but diver-
ently transcribed from each other, indicating a link between
arbon and nitrogen metabolism [2]. Of all the nitrogen control
ystems present in LAB, GlnR and CodY are the most stud-
ed. All LAB genomes posses GlnR but CodY is only present
n Lactocccus, Streptococcus  and Enterococcus  spp. GlnR is
nvolved in controlling the import of nitrogenous compounds
nd the synthesis of intracellular ammonia under high nitrogen
oncentrations [51], while CodY controls the proteolytic system
f L.  lactis  and particularly the cell-wall proteinase (PrtP), the
ey enzyme in milk degradation [52].
.  Mechanism  of  action  of  probiotics
The actual mechanism of action of probiotics has not been
learly understood, however, documented results are those
btained from animal models and in  vitro  experiments. One
ode of action of probiotics may be an improvement of the
arrier functions of the gut mucosa (Fig. 1). Several strains of
actobacillus  and Biﬁdobacterium  as well as structural compo-
ents, and microbial-produced metabolites are able to stimulate
pithelial cell signaling pathways [53]. The Nuclear Factor
appa-Light-Chain-Enhancer of activated B cells (NF-kB) path-
ay is modulated by probiotics at many different levels with
ffects seen on I Kappa B protein (IKB) degradation and
biquitination [123], proteosome function [122] and nuclear-
ytoplasmic movement of RelA through a PPAR-gamma
ependent pathway. Some probiotics such as S.  thermophilus
nd L.  acidophilus  alter the expression of tight junction proteins
nd/or their localization in both in  vivo  and in  vitro  models [54].
actobacillus  plantarum  MB452 has been shown to alter expres-
ion levels of genes coding for occludin, tubulin, proteasome
t
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nd certain cytoskeleton anchoring proteins [55]. Other probio-
ics boost gut barrier function through increased production of
ytoprotective molecules such as heat-shock proteins. In addi-
ion, probiotics are able to prevent cytokine and oxidant-induced
pithelial damage thereby promoting cell survival [121].
Probiotics may also modulate the immune system functions.
or instance, L.  acidophilus  has been found to modulate toll-like
eceptors and the proteoglycan recognition proteins of entero-
ytes, leading to activation of dendric cells and lymphocytes
-helper 1 responds. The resulting stimulation of lympho-
ytes T-helper 1 cytokines can suppress lymphocyte T-helper 2
esponses which provoke the atopic issues [120]. By this mech-
nism, the probiotics such as L. acidophilus, and Rhamnococcus
G decrease skin sensitivity in children and can reduce disor-
ers like eczema [56,57]. Another possible mechanism of action
f probiotics may be their ability to suppress the growth of
athogenic bacteria by producing broad spectrum bacteriocins
58]. Probiotics such as B.  infantis  Y1, L.  acidophilus  MB 443, L.
lantarum MB 452, L. paracasei  MB 451, L.  bulgaricus  MB453
nhibit pathogens from binding to gut cell walls and also produce
hort chain fatty acids (SCFA) which decrease the pH of the gut
o selectively favor the growth of desirable microbes [118,119].
ome strains of lactobacilli express human mucus-binding pili,
hich would enhance their ability for colonization [117].
.  Health  effects  of  probiotics
Though many human and animal studies have proved the
ealth effects of probiotic consumption [59–61,103], health
uthorities have only approved claims on (a) lactose intoler-
nce and lactose digestion and (b) cholesterol reduction mostly
ecause of biomarker deficiency. Probiotics research is still in
he early stages, and far more studies need to be conducted to
etermine the health benefits and safety of probiotics.
.1.  Cholesterol  reducing  ability
Cholesterol plays a vital role in many functions of the body,
uch as in the synthesis of steroidal hormones, but excessive
holesterol in the blood causes arterial clogging and increases
he risk of heart disease and/or stroke. The risk of heart attack
s three times higher in those with hypercholesterolemia, com-
ared to those who have normal blood lipid profiles [115]. The
holesterol reducing ability of probiotics has been extensively
eviewed by Ishimwe et al. [62]. In a randomized, double-blind,
lacebo-controlled, and parallel-designed study, L.  acidophilus
HO-220 and inulin was administered to thirty-two hyperc-
olesterolemic men and women. After 12 weeks, their plasma
otal cholesterol and low-density lipoprotein (LDL)-cholesterol
educed by 7.84 and 9.27%, respectively [63]. Many hypothe-
es have been proposed for the mechanism by which probiotics
ower cholesterol levels. The hypothesis include deconjugation
f bile via  bile salt hydrolase [111], binding of cholesterol
o probiotic cellular surface and incorporation of cholesterol
olecules into the probiotic cellular membrane, production of
hort-chain fatty acids from oligosaccharides, co-precipitation
f cholesterol with deconjugated bile [64] and cholesterol
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iig. 1. An overview of mechanisms involved in probiotic-induced enhanceme
ignaling pathways and tight junctions, as well as effects on microbial ecology,
onversion to coprostanolin [114]. Among all the hypothesis,
he bile salt hydroxylase theory is most popular. Liver hepa-
ocytes produce bile salts which enhance dietary cholesterol
nd fat transport across the intestinal epithelium. The primary
ile acids conjugate with either glycine to form glycocholic
cid (cholylglycine) or taurine to form taurocholic acid. Since
he conjugated bile salts are very soluble, most of them enter
nto enterohepatic circulation after absorption [113] resulting in
n accumulation in the blood. Studies have shown that many
iﬁdobacterium  and  Lactobacillus  species produce bile salt
ydrolase (BSH) which cleaves amide bonds between bile acids
nd their conjugates [65,112]. Probiotics BSH may therefore
ydrolyze conjugated bile acids to liberate free primary bile
cids which are less efficiently reabsorbed from the intestinal
umen and excreted in feces [111,112]. Such probiotics con-
aining active BSH increase the production of bile salts from
holesterol in their colonized area, thus reducing cholesterol
ssociated problems. Some Lactobacillus  species such as L.
cidophilus  possess protease-sensitive receptors on their cell
urface with which they bind tightly to exogenous cholesterol
r phosphatidylcholine vesicles and incorporate them into their
ell membranes [64,111]. Bacteria such as Sterolibacterium  den-
triﬁcans produce cholesterol dehydrogenase/isomerase which
atalyzes the conversion of cholesterol to cholest-4-en-3-one
hich is converted into coprostanol and excreted in feces [63].
ince probiotic cholesterol lowering ability is strain specific
62], strains that exhibit excellent properties still need to be iden-
ified. Secondary bile acids have been reported to disrupt DNA
epair pathway and cause oxidative stress in epithelial cells [66].
t
m
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g epithelial barrier function. These include direct modulation of epithelial cell
e and adaptive immune function [116].
his thus calls for more research on how BSH producing pro-
iotics may prevent risks such as sepsis or colon cancer due to
he secondary bile salts [67].
.2.  Urogenital  and  vaginal  health
The dominant microflora in a healthy human vagina is a
ariety of Lactobacillus  species which play essential roles in
rotecting women from genital infections. An alteration in the
opulation of lactobacilli can result in microbial imbalance in
he vagina, causing a quantitative and qualitative shift from nor-
ally occurring lactobacilli to a mixed microflora dominated by
naerobic bacteria such as Gardnerella  vaginalis, Bacteroides,
revotella, and Mobiluncus  species [68]. Such a condition is
ermed bacterial vaginosis. Infections that involve urogenital
icrobial flora imbalance such as yeast vaginitis, candidiasis,
acterial vaginosis, and urinary tract infection can be recurrent
35]. Current available antimicrobial treatments can often lead
o diarrhea, super infections, depression and even renal fail-
re. Moreover, antimicrobial resistance tends to decrease the
ffectiveness of this therapy over time. Lactobacilli have been
hown to produce biosurfactants and collagen-binding proteins
hat inhibit pathogen adhesion to cells. This may account for
hy the vaginal mucosa is dominated by lactobacilli making
t less receptive to pathogens [69]. Cell to cell communica-
ion could also be a mechanism by which probiotics stimulate
ucus production which serves as a barrier to pathogens and also
ignaling the anti-inflammatory cytokine production [70]. Fala-
as et al. [71] observed that lactobacilli can inhibit the growth of
nce a
C
s
t
t
w
r
[
g
L
b
h
l
[
u
e
p
a
6
b
b
d
a
l
p
A
t
b
t
t
t
a
s
a
[
t
r
S
p
s
I
g
m
o
h
6
t
a
p
(
o
t
t
l
t
i
(
m
a
m
t
d
(
m
o
r
t
l
i
a
m
t
i
w
d
m
l
o
f
r
t
g
O
m
c
p
a
i
t
l
f
t
p

o
t
e
P
[
7E.B.-M. Daliri, B.H. Lee / Food Scie
andida  albicans  and its adherence on the vaginal epithelium in
mall sample sizes. Presently, the only strains clinically shown
o have an effect are Lactobacillus  rhamnosus  GR-1 and Lac-
obacillus  reuteri  [72], when administered intra-vaginally once
eekly or twice daily orally, reduced recurrences of UTI and
estored a normal lactobacilli dominated vaginal flora in patients
73]. A recent study on the role of probiotics in a woman’s uro-
enital health confirms that supplemental probiotics containing
. rhamnosus  GR-1 and L.  reuteri  promote the colonization of
eneficial microbiota and may help to support overall vaginal
ealth [110]. Daily oral intake of L.  rhamnosus  and Lactobacil-
us fermentum  have also been shown to modify the vaginal flora
74]. Though many properties required by probiotics to confer
rogenital protection have been identified, yet evidence of their
xpression in  vivo  is scanty. To make this approach successful,
roper selection of strains, proof of concept, and efficacy must
ccompany products used in patients.
.3.  Oral  health
The human mouth harbors diverse microbiomes in the human
ody such as viruses, fungi, protozoa, archaea and bacteria. The
acteria cause two common diseases namely dental caries (tooth
ecay) and the periodontal (gum) diseases [75]. The balance of
ll these microorganisms can easily be disturbed and a preva-
ence of pathogenic organisms can lead to different oral health
roblems such as dental caries, periodontitis, and halitosis [76].
lthough the evidence for periodontitis is less than dental caries,
he use of probiotics to manage the oral microflora appears to
e an effective method to control oral conditions [109].
Probiotics marketed for oral health include species of Lac-
obacillus and Biﬁdobacterium  [77]. Many studies have shown
hat they can reduce oral levels of the cariogenic species Strep-
ococcus  mutans  [78,79,108]. Streptococcus  salivarius  K12 has
lso been identified to produces bacteriocins against pathogens
uch as Streptococcus  pyogenes  and Streptococcus  pneumonia,
nd prevents recurrent pharyngitis, otitis media, and tonsillitis
80,81]. In a double-blind, placebo-controlled trial administra-
ion of S.  salivarius  K12 reduced the occurrence of plaque and
educed levels of S.  mutans  in subjects [82]. Species such as
treptococcus uberis  and Streptococcus  oralis  also suppress
eriodontal pathogens [83]. Probiotics was effective on halito-
is and prevented the production of volatile sulfur compounds.
n addition, Vivekananda et al. [107] observed a reduction in
ingivitis and gum bleeding after L.  reuteri  administration. The
echanism by which these probiotics colonize and affect the
ral cavity is needed to better understand how they improve oral
ealth.
.4.  Lactose  intolerance
Lactose is an important nutrient in all mammalian neonates
hat almost all have the ability to digest lactose to glucose
nd galactose for a variable time after birth. In most human
opulations, lactase activity decreases during mid-childhood
about five years of age), resulting in low levels from that age
nwards. However, some people retain high levels of activity
c
r
b
bnd Human Wellness 4 (2015) 56–65 61
hroughout adult life. In humans, inheritance of lactase persis-
ent (LP: adults retain ability to digest lactose) is dominant and
actase-non persistent (LNP: adults lose ability to digest lac-
ose) is recessive [104]. When milk is ingested and the small
ntestine fails to produce enough lactase, Lactose intolerance
LI) or lactose malabsorption occurs. Colonic bacteria then
etabolize unabsorbed lactose producing hydrogen, methane
nd short chain fatty acids [106]. Lactose intolerance is deter-
ined by blood glucose concentrations, and breath hydrogen
est following ingestion of a lactose load. Also, a genetic
etection of C/T polymorphism at −13,910 upstream of LPH
lactase-phlorizin hydrolase) gene can also be used. Lactose
aldigestion may be classified as primary type (hypolactasia)
r secondary type. Primary maldigestion is due to an autosomal
ecessive condition which results in reduced lactase activi-
ies in the intestine [104]. On the other hand, secondary-type
actose maldigestion is thought to be due to a loss of small
ntestinal mucosa. Symptoms of lactose intolerance include
bdominal pain, bloating, flatulence and diarrhea, but the cause
ay be multifactorial. In humans, a decline in intestinal lac-
ase cannot be reversed by consuming lactose regular. Lactose
ngestion and digestion have several effects on health. People
ith lactose intolerance may avoid milk consumption and other
airy products, take lactase tablets or take probiotic supple-
ents to manage the condition. Another approach to manage
actose intolerance is to increase the lactose load steadily in
ne’s diet. This aids the colon to adapt slowly. Since lactase
rom intestinal brush border is not an inducible enzyme, the
eduction in symptoms may be explained by colonic adapta-
ion [102].
Microbial -galactosidase in yogurt is known to survive
astric passage and support lactose digestion. Ibrahim and
’Sullivan [84] observed that overproducing -galactosidase
utants improved symptoms of lactose malabsorption and milk
ontaining L.  acidophilus  also aids lactose absorption in LI
atients [126]. Probiotic supplementation can also alter the
mount of colonic microbiota and alleviate symptoms in lactose-
ntolerant subjects [101]. Alterations in colonic microbiota by
he supplementation might be one of the factors that alleviate
actose intolerance. Prebiotics are nondigestible (by the host)
ood ingredients that have a beneficial effect through their selec-
ive metabolism in the intestinal tract [103]. A wide range of
rebiotics have been isolated from plant materials, including
-glucans from oats, inulin from chicory root, many types of
ligosaccharides from lactose, starch, xylose, etc.  The combina-
ion of probiotics and prebiotic (called synbiotics) also increases
ffectiveness of probiotic preparations for therapeutic use [103].
rebiotics may also be effective in LI management and treatment
104,105] since they support the growth of probiotics.
.  Future  perspectives
From general gut health, to immune support, skin health,
holesterol control, maybe even sensorimotor behaviors, the
esearch thus continues to build. Over the past decade, there has
een extensive work in animal models on how probiotics and pre-
iotics modulate host metabolism. Studies with animal models
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ave shown that the gut microbiota can regulate inflammation,
diposity, satiety, energy expenditure and glucose metabolism.
s more knowledge on the mechanisms from in  vivo  experi-
ents is unraveling, there is a growing need to translate the
esults into humans. However, there are very few good, double-
lind, placebo-controlled clinical trials that can prove causality
f pro- and prebiotics on modulating human metabolism [62]. At
resent, high-quality human trials have demonstrated the poten-
ial for gut microbiota in manipulating and preventing or treating
isease such as hypercholesterolemia and obesity [12,85,86].
holesterol lowering effects of fermented dairy products and
ncapsulated bile salt hydrolase (BSH) were reported in animal
rials, with a reduction of 58% serum cholesterol level in rats
y oral feeding of encapsulated BSH [87]. Though cholesterol
educing probiotic L.  reuteri  NCIMB 30242 (Micropharma,
anada) has been on the market as the first recognized biomaker
f disease, in human trials, however, there are mixed outcomes
88,89]. This therefore calls for more work to carry out to iden-
ify strains with excellent activities as well as their mechanism
f action. Lebeer et al. [90] have reported an increase in anti-
nflammatory activity when lipoteichoic acid is removed from
actobacilli cell walls and this opens a new door to unraveling the
echanism by which probiotics work. Specific bacterial strains
an therefore be genetically modified to study their mechanisms
f action. Some animal studies have revealed that probiotics
roduce bioactive compounds which significantly contribute to
unctionality within the gastrointestinal tract [91]. Biﬁdobac-
erium breve, B.  biﬁdum, B.  pseudolongum  and Lactobacillus
onvert linoleic acid (LA) into conjugated linoleic acid, CLA
92,93] which suppresses multistage carcinogenesis at different
ites [94]. Lactobacillus  helveticus  and Biﬁdobacterium  longum
ave also been reported to produce and respond to mammalian
erotonin [95] and affect behavior modulation [96,97]. The
bility of these bacteria to produce as well as respond to neuro-
hemicals substantiates the potential of probiotics to influence
sychological health and general behavior as observed by Hsiao
t al. [98] and Tillisch et al. [99]. It is therefore probable that
odulating the gut microbiota with such biotherapeutics may
arget stress-related CNS disorders, including stress-induced
ognitive deficits [100]. However, elucidation of mechanisms
nd substantiation of animal studies in humans remain essential
esearch goals.
onﬂict  of  interest
The authors declare no conflict of interest.
eferences
[1] P. Turnbaugh, R. Ley, M. Hamady, C. Fraser-Liggett, R. Knight, J. Gor-
don, The human microbiome project, Nature 449 (2007) 804–810.
[2] F. Douillard, W. de Vos, Functional genomics of lactic acid bacteria: from
food to health, Microb. Cell Fact. 13 (Suppl. 1) (2014).
[3] F. Scaldaferri, V. Gerardi, L. Lopetuso, F. Del Zompo, F. Mangiola, I.
Bosˇkoski, G. Bruno, V. Petito, L. Laterza, G. Cammarota, E. Gaetani, A.
Sgambato, A. Gasbarrini, Gut microbial flora, prebiotics, and probiotics
in IBD: their current usage and utility, Biomed. Res. Int. 2013 (2013)
435268.nd Human Wellness 4 (2015) 56–65
[4] K. Pokusaeva, G. Fitzgerald, D. van Sinderen, Carbohydrate metabolism
in bifidobacteria, Genes Nutr. 6 (2011) 285–306.
[5] R. Gustafsson, S. Ahrné, B. Jeppsson, C. Benoni, C. Olsson, M. Stjern-
quist, B. Ohlsson, The Lactobacillus ﬂora in vagina and rectum of fertile
and postmenopausal healthy Swedish women, BMC Women’s Health 11
(2011) 17.
[6] A. Jenzsch, S. Eick, F. Rassoul, R. Purschwitz, H. Jentsch, Nutritional
intervention in patients with periodontal disease: clinical, immunological
and microbiological variables during 12 months, Br. J. Nutr. 101 (2009)
879–885.
[7] J. Cebra, Influences of microbiota on intestinal immune system develop-
ment, Am. J. Clin. Nutr. 69 (6) (1999) 1046s–1051s.
[8] L. Hooper, M. Wong, A. Thelin, L. Hansson, P. Falk, J. Gordon, Molec-
ular analysis of commensal host–microbial relationships in the intestine,
Science (New York, NY) 291 (2001) 881–884.
[9] J. Penders, E. Stobberingh, P. van den Brandt, C. Thijs, The role of the
intestinal microbiota in the development of atopic disorders, Allergy 62
(2007) 1223–1236.
[10] L. Hooper, T. Stappenbeck, C. Hong, J. Gordon, Angiogenins: a new class
of microbicidal proteins involved in innate immunity, Nat. Immunol. 4
(2003) 269–273.
[11] P. Scanlan, F. Shanahan, Y. Clune, J. Collins, G. O’Sullivan, M.
O’Riordan, E. Holmes, Y. Wang, J. Marchesi, Culture-independent anal-
ysis of the gut microbiota in colorectal cancer and polyposis, Environ.
Microbiol. 10 (2008) 789–798.
[12] K. Fujimura, N. Slusher, M. Cabana, S. Lynch, Role of the gut micro-
biota in defining human health, Expert Rev. Anti-Infect. Ther. 8 (2010)
435–454.
[13] C. Thum, A. Cookson, D. Otter, W. McNabb, A. Hodgkinson, J. Dyer, N.
Roy, Can nutritional modulation of maternal intestinal microbiota influ-
ence the development of the infant gastrointestinal tract? J. Nutr. 142
(2012) 1921–1928.
[14] M. Collado, M. Cernada, C. Baüerl, M. Vento, G. Pérez-Martínez, Micro-
bial ecology and host–microbiota interactions during early life stages, Gut
Microbes 3 (2012) 352–365.
[15] F. Guaraldi, G. Salvatori, Effect of breast and formula feeding on gut
microbiota shaping in newborns, Front. Cell. Infect. Microbiol. 2 (2012)
94.
[16] L. de Sousa Moraes, L. Grzeskowiak, T. de Sales Teixeira, M. Gou-
veia Peluzio, Intestinal microbiota and probiotics in celiac disease, Clin.
Microbiol. Rev. 27 (2014) 482–489.
[17] M. Uccello, G. Malaguarnera, F. Basile, V. D’Agata, M. Malaguarnera,
G. Bertino, M. Vacante, F. Drago, A. Biondi, Potential role of probiotics
on colorectal cancer prevention, BMC Surg. 12 (Suppl. 1) (2012).
[18] J. Zackular, M. Rogers, M. Ruffin, P. Schloss, The human gut microbiome
as a screening tool for colorectal cancer, Cancer Prev. Res. (Philadelphia,
PA) 7 (2014) 1112–1121.
[19] P. Bekkering, I. Jafri, F. van Overveld, G. Rijkers, The intricate association
between gut microbiota and development of type 1, type 2 and type 3
diabetes, Expert Rev. Clin. Immunol. 9 (2013) 1031–1041.
[20] I. Moreno-Indias, F. Cardona, F. Tinahones, M. Queipo-Ortun˜o, Impact
of the gut microbiota on the development of obesity and type 2 diabetes
mellitus, Front. Microbiol. 5 (2014) 190.
[21] A. Gomes, A. Bueno, R. de Souza, J. Mota, Gut microbiota, probiotics
and diabetes, Nutr. J. 13 (2014) 60.
[22] H. Tilg, A. Moschen, Microbiota and diabetes: an evolving relationship,
Gut 63 (2014) 1513–1521.
[23] S. Udayappan, A. Hartstra, G. Dallinga-Thie, M. Nieuwdorp, Intestinal
microbiota and faecal transplantation as treatment modality for insulin
resistance and type 2 diabetes mellitus, Clin. Exp. Immunol. 177 (2014)
24–29.
[24] S. Dillon, E. Lee, C. Kotter, G. Austin, Z. Dong, D. Hecht, S. Gianella,
B. Siewe, D. Smith, A. Landay, C. Robertson, D. Frank, C. Wilson, An
altered intestinal mucosal microbiome in HIV-1 infection is associated
with mucosal and systemic immune activation and endotoxemia, Mucosal
Immunol. 7 (2014) 983–994.
[25] E. Mutlu, A. Keshavarzian, J. Losurdo, G. Swanson, B. Siewe, C. Forsyth,
A. French, P. Demarais, Y. Sun, L. Koenig, S. Cox, P. Engen, P. Chakradeo,
nce aE.B.-M. Daliri, B.H. Lee / Food Scie
R. Abbasi, A. Gorenz, C. Burns, A. Landay, A compositional look at the
human gastrointestinal microbiome and immune activation parameters in
HIV infected subjects, PLoS Pathog. 10 (2014).
[26] N. Kamada, G. Nún˜ez, Role of the gut microbiota in the development and
function of lymphoid cells, J. Immunol. 190 (2013) 1389–1395.
[27] D. Gevers, S. Kugathasan, L. Denson, Y. Vázquez-Baeza, W. Van Treuren,
B. Ren, E. Schwager, D. Knights, S. Song, M. Yassour, X. Morgan, A.
Kostic, C. Luo, A. González, D. McDonald, Y. Haberman, T. Walters, S.
Baker, J. Rosh, M. Stephens, M. Heyman, J. Markowitz, R. Baldassano,
A. Griffiths, F. Sylvester, D. Mack, S. Kim, W. Crandall, J. Hyams, C.
Huttenhower, R. Knight, R. Xavier, The treatment-naive microbiome in
new-onset Crohn’s disease, Cell Host Microbe 15 (2014) 382–392.
[28] Y. Haberman, T.L. Tickle, P.J. Dexheimer, M.-O. Kim, D. Tang, R. Karns,
R.N. Baldassano, J.D. Noe, J. Rosh, J. Markowitz, M.B. Heyman, A.M.
Griffiths, W.V. Crandall, D.R. Mack, S.S. Baker, C. Huttenhower, D.J.
Keljo, J.S. Hyams, S. Kugathasan, T.D. Walters, B. Aronow, R.J. Xavier,
D. Gevers, L.A. Denson, Pediatric Crohn disease patients exhibit specific
ileal transcriptome and microbiome signature, J. Clin. Invest. 124 (2014)
3617–3633.
[29] J. Bjerrum, Y. Wang, F. Hao, M. Coskun, C. Ludwig, U. Günther, O.
Nielsen, Metabonomics of human fecal extracts characterize ulcerative
colitis, Crohn’s disease and healthy individuals, Metabolomics 11 (2015)
122–133.
[30] J. Kabeerdoss, V. Sankaran, S. Pugazhendhi, B. Ramakrishna, Clostrid-
ium leptum group bacteria abundance and diversity in the fecal microbiota
of patients with inflammatory bowel disease: a case–control study in India,
BMC Gastroenterol. 13 (2013) 20.
[31] M. Rooks, P. Veiga, L. Wardwell-Scott, T. Tickle, N. Segata, M. Michaud,
C. Gallini, C. Beal, J. van Hylckama-Vlieg, S. Ballal, X. Morgan, J.
Glickman, D. Gevers, C. Huttenhower, W. Garrett, Gut microbiome com-
position and function in experimental colitis during active disease and
treatment-induced remission, ISME J. 8 (2014) 1403–1417.
[32] M. Simrén, G. Barbara, H. Flint, B. Spiegel, R. Spiller, S. Vanner, E.
Verdu, P. Whorwell, E. Zoetendal, C. Rome Foundation, Intestinal micro-
biota in functional bowel disorders: a Rome foundation report, Gut 62
(2013) 159–176.
[33] K. Lee, O. Lee, D. Koh, W. Sohn, S. Lee, D. Jun, H. Lee, B. Yoon, H. Choi,
J. Hahm, Association between symptoms of irritable bowel syndrome and
methane and hydrogen on lactulose breath test, J. Korean Med. Sci. 28
(2013) 901–907.
[34] M. Sherman, J. Minnerly, W. Curtiss, S. Rangwala, S. Kelley, Research on
neonatal microbiomes: what neonatologists need to know, Neonatology
105 (2014) 14–24.
[35] I. Lee, Critical pathogenic steps to high risk Helicobacter pylori gastritis
and gastric carcinogenesis, World J. Gastroenterol. 20 (2014) 6412–6419.
[36] R. Torrazza, J. Neu, The altered gut microbiome and necrotizing entero-
colitis, Clin. Perinatol. 40 (2013) 93–108.
[37] A. Morrow, A. Lagomarcino, K. Schibler, D. Taft, Z. Yu, B. Wang, M.
Altaye, M. Wagner, D. Gevers, D. Ward, M. Kennedy, C. Huttenhower,
D. Newburg, Early microbial and metabolomic signatures predict later
onset of necrotizing enterocolitis in preterm infants, Microbiome 1 (2013)
13–16.
[38] R. Ley, Obesity and the human microbiome, Curr. Opin. Gastroenterol.
26 (2010) 5–11.
[39] I. Harley, C. Karp, Obesity and the gut microbiome: striving for causality,
Mol. Metab. 1 (2012) 21–31.
[40] F. Matarazzo, A. Ribeiro, M. Faveri, C. Taddei, M. Martinez, M. Mayer,
The domain Archaea in human mucosal surfaces, Clin. Microbiol. Infect.
18 (2012) 834–840.
[41] K. Harris, A. Kassis, G. Major, C. Chou, Is the gut microbiota a new factor
contributing to obesity and its metabolic disorders? J. Obesity 2012 (2012)
879151.
[42] M. Glick-Bauer, M.-C. Yeh, The health advantage of a vegan diet: explor-
ing the gut microbiota connection, Nutrients 6 (2014) 4822–4838.[43] M. Bedaiwi, R. Inman, Microbiome and probiotics: link to arthritis, Curr.
Opin. Rheumatol. 26 (2014) 410–415.
[44] M. Ogrendik, Rheumatoid arthritis is an autoimmune disease caused by
periodontal pathogens, Int. J. Gen. Med. 6 (2013) 383–386.nd Human Wellness 4 (2015) 56–65 63
[45] V. Taneja, Arthritis susceptibility and the gut microbiome, FEBS Lett.
588 (2014) 4244–4249.
[46] Z. Guo, X. Liu, Q. Zhang, Z. Shen, F. Tian, H. Zhang, Z. Sun, H. Zhang, W.
Chen, Influence of consumption of probiotics on the plasma lipid profile:
a meta-analysis of randomised controlled trials, Nutr. Metab. Cardiovasc.
Dis. 21 (2011) 844–850.
[47] A. Bordoni, A. Amaretti, A. Leonardi, E. Boschetti, F. Danesi, D.
Matteuzzi, L. Roncaglia, S. Raimondi, M. Rossi, Cholesterol-lowering
probiotics: in vitro selection and in vivo testing of bifidobacteria, Appl.
Microbiol. Biotechnol. 97 (2013) 8273–8281.
[48] B. Johnson, T. Klaenhammer, Impact of genomics on the field of probio-
tic research: historical perspectives to modern paradigms, Antonie Van
Leeuwenhoek 106 (2014) 141–156.
[49] M. Marcó, S. Moineau, A. Quiberoni, Bacteriophages and dairy fermen-
tations, Bacteriophage 2 (2012) 149–158.
[50] E. Luesink, R. van Herpen, B. Grossiord, O. Kuipers, W. de Vos, Trans-
criptional activation of the glycolytic las operon and catabolite repression
of the gal operon in Lactococcus lactis are mediated by the catabolite
control protein CcpA, Mol. Microbiol. 30 (1998) 789–798.
[51] T. Groot Kormelink, E. Koenders, Y. Hagemeijer, L. Overmars, R. Siezen,
W. de Vos, C. Francke, Comparative genome analysis of central nitrogen
metabolism and its control by GlnR in the class Bacilli, BMC Genomics
13 (2012) 191.
[52] J. Marugg, R. van Kranenburg, P. Laverman, G. Rutten, W. de Vos, Iden-
tical transcriptional control of the divergently transcribed prtP and prtM
genes that are required for proteinase production in Lactococcus lactis
SK11, J. Bacteriol. 178 (1996) 1525–1531.
[53] V. Stetinova, L. Smetanova, J. Kvetina, Z. Svoboda, Z. Zidek, H.
Tlaskalova-Hogenova, Caco-2 cell monolayer integrity and effect of pro-
biotic Escherichia coli Nissle 1917 components, Neuro Endocrinol. Lett.
31 (Suppl 2) (2010) 51–56.
[54] S. Resta-Lenert, K. Barrett, Live probiotics protect intestinal epithelial
cells from the effects of infection with enteroinvasive Escherichia coli
(EIEC), Gut 52 (2003) 988–997.
[55] R. Anderson, A. Cookson, W. McNabb, Z. Park, M. McCann, W. Kelly,
N. Roy, Lactobacillus plantarum MB452 enhances the function of the
intestinal barrier by increasing the expression levels of genes involved in
tight junction formation, BMC Microbiol. 10 (2010) 316.
[56] K. Wickens, P. Black, T. Stanley, E. Mitchell, P. Fitzharris, G. Tan-
nock, G. Purdie, J. Crane, G. Probiotic Study, A differential effect of
2 probiotics in the prevention of eczema and atopy: a double-blind, ran-
domized, placebo-controlled trial, J. Allergy Clin. Immunol. 122 (2008)
788–794.
[57] C. West, M.-L. Hammarström, O. Hernell, Probiotics during weaning
reduce the incidence of eczema, Pediatr. Allergy Immunol. 20 (2009)
430–437.
[58] H. Hardy, J. Harris, E. Lyon, J. Beal, A. Foey, Probiotics, prebi-
otics and immunomodulation of gut mucosal defences: homeostasis and
immunopathology, Nutrients 5 (2013) 1869–1912.
[59] D. DiRienzo, Effect of probiotics on biomarkers of cardiovascular disease:
implications for heart-healthy diets, Nutr. Rev. 72 (2014) 18–29.
[60] J. Gilbert, R. Krajmalnik-Brown, D. Porazinska, S. Weiss, R. Knight,
Toward effective probiotics for autism and other neurodevelopmental
disorders, Cell 155 (2013) 1446–1448.
[61] M. Jones, C. Martoni, S. Prakash, Oral supplementation with probiotic L.
reuteri NCIMB 30242 increases mean circulating 25-hydroxyvitamin D:
a post hoc analysis of a randomized controlled trial, J. Clin. Endocrinol.
Metab. 98 (2013) 2944–2951.
[62] N. Ishimwe, E. Daliri, B. Lee, F. Fang, G. Du, The perspective on
cholesterol-lowering mechanisms of probiotics, Mol. Nutr. Food Res. 59
(2015) 94–105.
[63] L.-G. Ooi, M.-T. Liong, Cholesterol-lowering effects of probiotics and
prebiotics: a review of in vivo and in vitro findings, Int. J. Mol. Sci. 11
(2010) 2499–2522.[64] M. Kumar, R. Nagpal, R. Kumar, R. Hemalatha, V. Verma, A. Kumar,
C. Chakraborty, B. Singh, F. Marotta, S. Jain, H. Yadav, Cholesterol-
lowering probiotics as potential biotherapeutics for metabolic diseases,
Exp. Diabetes Res. 2012 (2012) 902917.
6 nce a4 E.B.-M. Daliri, B.H. Lee / Food Scie
[65] J. Chae, V. Valeriano, G.B. Kim, D.K. Kang, Molecular cloning, char-
acterization and comparison of bile salt hydrolases from Lactobacillus
johnsonii PF01, J. Appl. Microbiol. 114 (2013) 121–133.
[66] H. Ajouz, D. Mukherji, A. Shamseddine, Secondary bile acids: an under-
recognized cause of colon cancer, World J. Surg. Oncol. 12 (2014)
164.
[67] R. Martín, S. Miquel, J. Ulmer, N. Kechaou, P. Langella, L. Bermúdez-
Humarán, Role of commensal and probiotic bacteria in human health: a
focus on inflammatory bowel disease, Microb. Cell Fact. 12 (2013) 71.
[68] L. Petricevic, K. Domig, F. Nierscher, M. Sandhofer, M. Fidesser, I. Kro-
ndorfer, P. Husslein, W. Kneifel, H. Kiss, Characterisation of the vaginal
Lactobacillus microbiota associated with preterm delivery, Sci. Rep. 4
(2014) 5136.
[69] S. Waigankar, V. Patel, Role of probiotics in urogenital healthcare, J.
Mid-life Health 2 (2011) 5–10.
[70] T. Pessi, Y. Sütas, M. Hurme, E. Isolauri, Interleukin-10 generation in
atopic children following oral Lactobacillus rhamnosus GG, Clin. Exp.
Allergy 30 (2000) 1804–1808.
[71] M. Falagas, G. Betsi, S. Athanasiou, Probiotics for prevention of recurrent
vulvovaginal candidiasis: a review, J. Antimicrob. Chemother. 58 (2006)
266–272.
[72] D. Commane, R. Hughes, C. Shortt, I. Rowland, The potential mecha-
nisms involved in the anti-carcinogenic action of probiotics, Mutat. Res.
591 (2005) 276–289.
[73] G. Reid, A. Bruce, Probiotics to prevent urinary tract infections: the
rationale and evidence, World J. Urol. 24 (2006) 28–32.
[74] G. Reid, D. Beuerman, C. Heinemann, A. Bruce, Probiotic Lactobacil-
lus dose required to restore and maintain a normal vaginal flora, FEMS
Immunol. Med. Microbiol. 32 (2001) 37–41.
[75] W. Wade, The oral microbiome in health and disease, Pharmacol. Res. 69
(2013) 137–143.
[76] S. Elavarasu, P. Jayapalan, T. Murugan, Bugs that debugs: probiotics, J.
Pharm. Bioall. Sci. 4 (2012) 22.
[77] J. Banas, E. Popp, Recovery of viable bacteria from probiotic products
that target oral health, Probiotics Antimicrob. Proteins 5 (2013) 227–231.
[78] K. Anilkumar, A. Monisha, Role of friendly bacteria in oral health – a
short review, Oral Health Prev. Dent. 10 (2012) 3–8.
[79] B. Bizzini, G. Pizzo, G. Scapagnini, D. Nuzzo, S. Vasto, Probiotics and
oral health, Curr. Pharm. Des. 18 (2012) 5522–5531.
[80] F. Di Pierro, T. Adami, G. Rapacioli, N. Giardini, C. Streitberger, Clinical
evaluation of the oral probiotic Streptococcus salivarius K12 in the pre-
vention of recurrent pharyngitis and/or tonsillitis caused by Streptococcus
pyogenes in adults, Expert Opin. Biol. Ther. 13 (2013) 339–343.
[81] F. Di Pierro, M. Colombo, A. Zanvit, P. Risso, A. Rottoli, Use of Strep-
tococcus salivarius K12 in the prevention of streptococcal and viral
pharyngotonsillitis in children, Drug Healthcare Patient Saf. 6 (2014)
15–20.
[82] J. Burton, B. Drummond, C. Chilcott, J. Tagg, W. Thomson, J. Hale,
P. Wescombe, Influence of the probiotic Streptococcus salivarius strain
M18 on indices of dental health in children: a randomized double-blind,
placebo-controlled trial, J. Med. Microbiol. 62 (2013) 875–884.
[83] J. Hillman, E. McDonell, C. Hillman, R. Zahradnik, M. Soni, Safety
assessment of ProBiora3, a probiotic mouthwash: subchronic toxicity
study in rats, Int. J. Toxicol. 28 (2009) 357–367.
[84] S. Ibrahim, D. O’Sullivan, Use of chemical mutagenesis for the isolation
of food grade beta-galactosidase overproducing mutants of bifidobacte-
ria, lactobacilli and Streptococcus thermophilus, J. Dairy Sci. 83 (2000)
923–930.
[85] E. Dewulf, P. Cani, S. Claus, S. Fuentes, P. Puylaert, A. Neyrinck, L.
Bindels, W. de Vos, G. Gibson, J.-P. Thissen, N. Delzenne, Insight into
the prebiotic concept: lessons from an exploratory, double blind inter-
vention study with inulin-type fructans in obese women, Gut 62 (2013)
1112–1121.
[86] P. van Baarlen, F. Troost, C. van der Meer, G. Hooiveld, M. Boekschoten,
R. Brummer, M. Kleerebezem, Human mucosal in vivo transcriptome
responses to three lactobacilli indicate how probiotics may modulate
human cellular pathways, Proc. Natl. Acad. Sci. U.S.A. 108 (1 Suppl)
(2011) 4562–4569.nd Human Wellness 4 (2015) 56–65
[87] N. Sridevi, P. Vishwe, A. Prabhune, In vivo cholesterol reduction studies,
Food Res. Int. 42 (2009) 516–520.
[88] A.K. Patel, R.R. Singhania, A. Pandey, S.B. Chincholkar, Probiotic bile
salt hydrolase: current developments and perspectives, Appl. Biochem.
Biotechnol. 162 (2010) 166–180.
[89] Z. Guo, X.M. Liu, Q.X. Zhang, Z. Shen, F.W. Tian, H. Zhang, Z.H.
Sun, H.P. Zhang, W. Chen, Influence of consumption of probiotics on
the plasma lipid profile: a meta-analysis of randomised controlled trials,
Nutr. Metab. Cardiovasc. Dis. 21 (2011) 844–850.
[90] S. Lebeer, J. Vanderleyden, S. De Keersmaecker, Host interactions of
probiotic bacterial surface molecules: comparison with commensals and
pathogens, Nat. Rev. Microbiol. 8 (2010) 171–184.
[91] E. O’Shea, P. Cotter, C. Stanton, R. Ross, C. Hill, Production of bioactive
substances by intestinal bacteria as a basis for explaining probiotic mech-
anisms: bacteriocins and conjugated linoleic acid, Int. J. Food Microbiol.
152 (2012) 189–205.
[92] M. Macouzet, N. Robert, B. Lee, Genetic and functional aspects
of linoleate isomerase in Lactobacillus acidophilus, Appl. Microbiol.
Biotechnol. 87 (2010) 1737–1742.
[93] V. Dubey, A. Ghosh, B. Mandal, Appraisal of conjugated linoleic acid pro-
duction by probiotic potential of Pediococcus spp. GS4, Appl. Biochem.
Biotechnol. 168 (2012) 1265–1276.
[94] K. Lee, H. Lee, H. Cho, Y. Kim, Role of the conjugated linoleic acid in
the prevention of cancer, Crit. Rev. Food Sci. Nutr. 45 (2005) 135–144.
[95] M. Lyte, Probiotics function mechanistically as delivery vehicles for neu-
roactive compounds: microbial endocrinology in the design and use of
probiotics, Bioessays 33 (2011) 574–581.
[96] P. Bercik, E. Verdu, J. Foster, J. Macri, M. Potter, X. Huang, P. Mali-
nowski, W. Jackson, P. Blennerhassett, K. Neufeld, J. Lu, W. Khan, I.
Corthesy-Theulaz, C. Cherbut, G. Bergonzelli, S. Collins, Chronic gas-
trointestinal inflammation induces anxiety-like behavior and alters central
nervous system biochemistry in mice, Gastroenterology 139 (2010)
2102–21120.
[97] T. Didari, S. Mozaffari, S. Nikfar, M. Abdollahi, Effectiveness of pro-
biotics in irritable bowel syndrome: updated systematic review with
meta-analysis, World J. Gastroenterol. 21 (2015) 3072–3084.
[98] E. Hsiao, S. McBride, S. Hsien, G. Sharon, E. Hyde, T. McCue, J. Codelli,
J. Chow, S. Reisman, J. Petrosino, P. Patterson, S. Mazmanian, Micro-
biota modulate behavioral and physiological abnormalities associated
with neurodevelopmental disorders, Cell 155 (2013) 1451–1463.
[99] K. Tillisch, J. Labus, L. Kilpatrick, Z. Jiang, J. Stains, B. Ebrat, D. Guyon-
net, S. Legrain-Raspaud, B. Trotin, B. Naliboff, E. Mayer, Consumption
of fermented milk product with probiotic modulates brain activity, Gas-
troenterology 144 (2013) 1394.
[100] R. Greer, A. Morgun, N. Shulzhenko, Bridging immunity and lipid
metabolism by gut microbiota, J. Allergy Clin. Immunol. 132 (2013)
253.
[101] A.E. Foxx-Orenstein, W.D. Chey, Manipulation of the gut microbiota as
a novel treatment strategy for gastrointestinal disorders, Am. J. Gastroen-
terol. Suppl. 1 (2012).
[102] T.S. Wilt, T. Tatyana, M. Brent, T. Roderick, R. James, S. Indulis, R.
Kane, M. Levitt, Lactose intolerance and health, Evidence Rep. Technol.
Ass. 192 (2010) 1–410.
[103] Y.J. Baek, B.H. Lee, Probiotics and prebiotics as bioactive components in
dairy products, in: Y.W. Park (Ed.), Bioactive Components in Milk Dairy
Products, Wiley-Blackwell Publ, New York, 2009, p. 449.
[104] B.H. Lee, M.T. Liong, S.B. Choi, Probiotics in health and disease, in: V.
Ravishankar Rai, J.A. Bai (Eds.), Beneficial Microbes in Fermented and
Functional Foods, CRC Press, 2014, pp. 167–183.
[105] B.H. Lee, Fundamentals of Food Biotechnology, 2nd ed., Wiley Black-
well, UK, 2015, pp. 518.
[106] P.M. Barling, Lactose tolerance and intolerance in Malaysians, IeJSME
6 (Suppl. 1) (2012) S12–S23.
[107] M.R. Vivekananda, K.L. Vandana, K.G. Bhat, Effect of the probiotic Lac-
tobacilli peuteri (Prodentis) in the management of periodontal disease: a
preliminary randomized clinical trial, J. Oral Microbiol. 2 (2010) 1–9.
[108] A. Haukioja, Probiotics and oral health, Eur. J. Dent. 4 (2010) 348–355.
[109] D.M. Bowen, Probiotics and oral health, J. Dent. Hyg. 87 (2013) 5–9.
nce aE.B.-M. Daliri, B.H. Lee / Food Scie
[110] G. Vujic, A.J. Knez, V.D. Stefanovic, V.K. Vrbanovic, Efficacy of orally
applied probiotic capsules for bacterial vaginosis and other vaginal infec-
tions: a double blind, randomnized, placebo controlled study, Eur. J. Obst.
Gynecol. Reprod. Biol. 168 (2013) 75–79.
[111] H.S. Lye, G.R. Rahmat-Ali, M.T. Liong, Mechanisms of cholesterol
removal by lactobacilli under conditions that mimic the human gastroin-
testinal tract, Int. Dairy J. 20 (2010) 169–175.
[112] X. Wang, J. Wang, F. Wu, Y. Sui, L. Yang, Z. Wang, Lactobacillus plan-
tarum strains as potential probiotic cultures with cholesterol-lowering
activity, J. Dairy Sci. 96 (2013) 2746–2753.
[113] O. McAuliffe, R.J. Cano, R. Klaenhammer, Genetic analysis of two bile
salt hydrolase activities in Lactobacillus acidophilus NCFM, Appl. Envi-
ron. Microbiol. 71 (2005) 4925–4929.
[114] G. Philippe, Metabolism of cholesterol and bile acids by the gut micro-
biota, Pathogens 3 (2014) 14–24.
[115] A.R. Ghosh, Appraisal of probiotics and prebiotics in gastrointestinal
infections, Webmed Central Gastroenterol. 3 (10) (2012) WMC003796.
[116] K.L. Madsen, Enhancement of epithelial barrier function by probiotics,
J. Epithelial Biol. Pharmacol 5 (Suppl. 1-M8) (2012) 55–59.
[117] F. Turroni, F. Serafini, E. Foroni, S. Duranti, M.O. Motherway, V. Tav-
erniti, M. Mangifesta, C. Milani, A. Viappiani, T. Roversi, B. Sánchez,
A. Santoni, L. Gioiosa, A. Ferrarini, M. Delledonne, A. Margolles, L.
Piazza, P. Palanza, A. Bolchi, S. Guglielmetti, D. van Sinderen, M. Ven-
tura, Role of sortase-dependent pili of Biﬁdobacterium biﬁdum PRL2010
in modulating bacterium–host interactions, Proc. Natl. Acad. Sci. U.S.A.
110 (27) (2013) 11151–11156.
[118] Y.K. Lee, Effects of diet on gut microbiota profile and the implications for
health and disease, Biosci. Microbiota Food Health 32 (1) (2013) 1–12.
[119] T. Rinttilä, J. Apajalahti, Intestinal microbiota and metabolites—
implications for broiler chicken health and performance, J. Appl. Poult.
Res. 22 (3) (2013) 647–658.
[120] C. Lorenzo, M. Laura, S. Veronica, L. Francesco, A. Francesco, T helper
cells plasticity in inflammation, Cytometry A 85 (1) (2014) 36–42.[121] H.Y. Liu, S. Roos, H. Jonsson, D. Ahl, J. Dicksved, J.E. Lindberg, T.
Lundh, Effects of Lactobacillus johnsonii and Lactobacillus reuteri on
gut barrier function and heat shock proteins in intestinal porcine epithelial
cells, Physiol. Rep. 3 (4) (2015) e12355S.nd Human Wellness 4 (2015) 56–65 65
[122] R. Shiou, Y. Yu, Y. Guo, S.M. He, C.H.M. Andrew, J. Hoenig, J. Sun, E.O.
Petrof, E.C. Claud, Synergistic protection of combined probiotic con-
ditioned media against neonatal necrotizing enterocolitis-like intestinal
injury, PLoS ONE 8 (5) (2013) e65108.
[123] C.M. Thomas, J. Versalovic, Probiotics-host communication: modulation
of signaling pathways in the intestine, Gut Microbes 1 (3) (2010) 148–163.
[124] D. Harzallah, H. Belhadj, Lactic acid bacteria as probiotics: charac-
teristics, selection criteria and role in immunomodulation of human
GI muccosal barrier, in: Intech Open Science/Open Minds, 2013,
http://dx.doi.org/10.5772/50732.
[125] FAO/WHO, Guidelines for the evaluation of probiotics in food, 2002,
ftp://ftp.fao.org/es/esn/food/wgreport2.pdf. 26/4/2015
[126] Y.J. Goh, T.R. Klaenhammer, A functional glycogen biosynthesis path-
way in Lactobacillus acidophilus: expression and analysis of the glg
operon, Mol. Microbiol. 89 (2013) 1187–1200.
[127] T. Raveh-Sadka, B.C. Thomas, A. Singh, B. Firek, B. Brooks, C.J.
Castelle, J.F. Banfield, Gut bacteria are rarely shared by co-hospitalized
premature infants, regardless of necrotizing enterocolitis development,
eLife 4 (2015) e05477.
[128] X.C. Morgan, T.L. Tickle, H. Sokol, D. Gevers, K.L. Devaney, D.V.
Ward, J.A. Reyes, S.A. Shah, N. LeLeiko, S.B. Snapper, A. Bousvaros,
J. Korzenik, B.E. Sands, R.J. Xavier, C. Huttenhower, Dysfunction of
the intestinal microbiome in inflammatory bowel disease and treatment,
Genome Biol. 13 (9) (2012) R79.
[129] S.S. Walters, A. Quiros, M. Rolston, I. Grishina, J. Li, Analysis of gut
microbiome and diet modification in patients with Crohn’s disease, SOJ
Microbiol. Infect. Dis. 2 (2014) 1–13.
[130] R.D. Cagno, M.D. Angelis, I. De Pasquale, M. Ndagijimana, P. Vernocchi,
P. Ricciuti, F. Gagliardi, L. Laghi, C. Crecchio, M.E. Guerzoni, M. Gob-
betti, R. Francavilla, Duodenal and faecal microbiota of celiac children:
molecular, phenotype and metabolome characterization, BMC Microbiol.
11 (2011) 219.
[131] S. Kumar, A. Bansal, A. Chakrabarti, S. Singhi, Evaluation of efficacy of
probiotics in prevention of candida colonization in a PICU—a randomized
controlled trial, Crit. Care Med. 41 (2013) 565–572.
[132] J. Versalovic, The human microbiome and probiotics: implications for
pediatrics, Ann. Nutr. Metab. 63 (Suppl. 2) (2013) 42–52.
